Akba Conversation (2024)

1. Akebia Therapeutics, Inc. (AKBA) Stock Forum & Discussion

AKBA - Akebia Therapeutics, Inc.
Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

See details ›

2. Akebia Therapeutics, Inc. (AX9.F) Stock Forum & Discussion

Find the latest Akebia Therapeutics, Inc. (AX9.F) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders ...
Find the latest Akebia Therapeutics, Inc. (AX9.F) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

See details ›

3. AKBA Akebia Therapeutics Inc. - Stocktwits

About · News · Earnings · Fundamentals
Track Akebia Therapeutics Inc. (AKBA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

See details ›

4. NASDAQ:AKBA - Akebia Therapeutics, Inc. - TradingView

View live Akebia Therapeutics, Inc. chart to track its stock's price action. Find market predictions, AKBA financials and market news.
See Also
Bridgeway Diagnostic Auburn Al Discover George Mason's Legacy - U.S. Constitution.net Chandler Basis Calendar Ceton Village Diggy

See details ›

5. AKBA: Akebia Therapeutics Inc - Stock Price, Quote and News - CNBC

Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

See details ›

6. NDAQ:AKBA | Stock Discussion | Akebia Therapeutics Inc - Stockhouse

Get stock insights, analysis and discussion about Akebia Therapeutics Inc (NDAQ:AKBA). Join the AKBA discussion on Canada's largest online investor ...
Get insights, analysis and discussion about Akebia Therapeutics Inc (NDAQ:AKBA) from Canada’s largest online community of active investors.

See details ›

7. Akebia Therapeutics Inc (AKBA) Stock Message Board | InvestorsHub

Find the latest Akebia Therapeutics Inc (AKBA) discussion and analysis from iHub's community of investors.

See details ›

8. Akebia Receives FDA Acceptance of Resubmission to NDA of ...

Oct 25, 2023 · PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...
See Also
715 Henry Ave

See details ›

9. Akebia Therapeutics (AKBA)- Vadadustat FDA Approved AT LAST!!

Mar 28, 2024 · Lastly, we have a full slate of conversation and tradeshows where we plan to introduce Vase to healthcare professionals that culminate with ...
Akebia Therapeutics (AKBA)- Vadadustat FDA Approved AT LAST!! - quote Is this a “sell the news” situation? /quote Yes :lol:

See details ›

10. Foreign Minister Wang Yi Holds Telephone Conversation with His ...

On March 21, 2013, Chinese Foreign Minister Wang Yi exchanged views on bilateral relations with his Iranian counterpart Ali Akba Salehi over the phone.
Foreign Minister Wang Yi Holds Telephone Conversation with His Iranian Counterpart Ali Akba Salehi

See details ›

11. AKBA Conversations From StockTwits - StockNews

Aug 14, 2021 · Will post Telegram to join my team once posts complete, follow and don't miss out! Have a blessed weekend! ... Micro DD - In March, Akebia ...
$AKBAMarket Price - $2.56Average Hold - $3.40Accumulate - Sub $2.45 (raised from $2.30)Price Target - $5Estimated Time Hold - 2QSupport - $2.75, $3.40Floor - $2.09Double Down Target - Sub $2Option - N/AMicro DD - In March, Akebia submitted an NDA to the FDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. In late May, the FDA accepted for filing the NDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. The FDA assigned the application a standard review and a PDUFA target action date of March 29, 2022. Cash, cash equivalents and available-for-sale securities as of June 30, 2021 were $247.0 million .

See details ›

12. Akebia Therapeutics Inc. (AKBA) News, Articles, Events ... - Stocktwits

Find Akebia Therapeutics Inc. (AKBA) news ... Get access to real time conversations, investor sentiment, price predictions and customized watchlists.
Find Akebia Therapeutics Inc. (AKBA) news, corporate events, press releases, latest company updates and headlines

See details ›

13. Akebia Therapeutics, Inc. (AKBA) Stock Price, Quote & News

(AKBA). NASDAQ: AKBA · Real-Time Price · USD. Add to Watchlist. 1.530. +0.060 ... News. All; Videos; PressPress Releases; Conversation. Akebia Therapeutics, Inc ...
Get a real-time Akebia Therapeutics, Inc. (AKBA) stock price quote with breaking news, financials, statistics, charts and more.

See details ›

14. Akebia Therapeutics (AKBA) Stock Price, News & Info | The Motley Fool

Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis ... Discussion Boards · Calculators · Financial Dictionary. Affiliates & ...
Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis.

See details ›

FAQs

Is AKBA stock a good buy? ›

The average analyst rating for AKBA stock from 2 stock analysts is "Strong Buy".

Get More Info ›

Will AKBA stock go up after FDA approval? ›

Akebia Therapeutics (NASDAQ:AKBA) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months.

Find Out More ›

Why is AKBA stock down? ›

AKBA stock results show that Akebia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

What is the AKBA forecast for 2024? ›

On average, 2 Wall Street analysts forecast AKBA's earnings for 2024 to be -$39,954,760, with the lowest AKBA earnings forecast at -$46,263,406, and the highest AKBA earnings forecast at -$33,646,114.

See Details ›

What is the price prediction for AKBA in 2030? ›

Akebia Therapeutics Stock Prediction 2030

In 2030, the Akebia Therapeutics stock will reach $ 0.742625 if it maintains its current 10-year average growth rate. If this Akebia Therapeutics stock prediction for 2030 materializes, AKBA stock will grow -44.58% from its current price.

Read On ›

Who owns AKBA stock? ›

Largest shareholders include BlackRock Inc., Vanguard Group Inc, Satter Management Co., L.p., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, Acadian Asset Management Llc, Renaissance Technologies Llc, State Street Corp, VEXMX - Vanguard Extended Market Index Fund Investor ...

Find Out More ›

Who are AKBA competitors? ›

Compare To: AKBA

AKBA. Akebia Therapeutics, Inc. Industry Drug Manufacturers—Specialty & Generic.
AQST. Aquestive Therapeutics, Inc. ...
AMRX. Amneal Pharmaceuticals, Inc. ...
ASRT. Assertio Holdings, Inc. ...
ESPR. Esperion Therapeutics, Inc. ...
EVOK. Evoke Pharma, Inc. ...
RMTI. Rockwell Medical, Inc. ...
SCYX. SCYNEXIS, Inc.

More items...

Discover More ›

What is the future of Akebia Therapeutics? ›

Average Price Target. Based on 2 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $4.50 with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 202.01% change from the last price of $1.49.

How much cash does Akebia have? ›

Cash on Hand as of June 2024 : $39.49 M

According to Akebia Therapeutics's latest financial reports the company has $39.49 M in cash and cash equivalents. A company's cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

See Details ›

What is Akebia stock prediction for 2025? ›

According to analysts, AKBA price target is 5.50 USD with a max estimate of 7.50 USD and a min estimate of 4.00 USD.

Find Out More ›

Is AX stock a good buy? ›

Axos Financial has 28.93% upside potential, based on the analysts' average price target. Is AX a Buy, Sell or Hold? Axos Financial has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.

View Details ›

Why is root stock dropping? ›

"Root's stock decline ... can be attributed to a combination of factions, including broader market dynamics and a shift in investor sentiment toward the insurtech sector," Hertz said. Root's stock has been volatile in recent history.

Discover More ›

Will 2024 be a good year for the stock market? ›

Market Sectors To Watch In 2024

Analysts project 11.5% earnings growth and 5.5% revenue growth for S&P 500 companies in 2024. Fortunately, analysts see positive earnings and revenue growth for all eleven market sectors this year.

Know More ›

What is the TLRY prediction for 2025? ›

According to analysts, TLRY price target is 2.44 USD with a max estimate of 4.00 USD and a min estimate of 2.00 USD.

Find Out More ›

What are the economists predictions for 2024? ›

Global inflation is forecast to decline steadily, from 6.8 percent in 2023 to 5.9 percent in 2024 and 4.5 percent in 2025, with advanced economies returning to their inflation targets sooner than emerging market and developing economies. Core inflation is generally projected to decline more gradually.

Explore More ›

Is Vulcan a good stock to buy? ›

Vulcan Materials Company's analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

What is the price target for Akebia Therapeutics? ›

Based on short-term price targets offered by three analysts, the average price target for Akebia Therapeutics comes to $5.17. The forecasts range from a low of $4.00 to a high of $7.50. The average price target represents an increase of 259.03% from the last closing price of $1.44.